Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Genprex, Inc. is actively participating in the 43rd Annual J.P. Morgan Healthcare Conference to engage with investors and industry stakeholders regarding its gene therapies for cancer and diabetes [1][2]. Company Overview - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing innovative technologies to deliver disease-fighting genes [4]. - The company’s lead product candidate, Reqorsa® Gene Therapy, is under evaluation in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), both of which have received Fast Track Designation from the FDA [4]. - Genprex's diabetes gene therapy, GPX-002, aims to transform pancreatic alpha cells into functional beta-like cells to produce insulin, targeting both Type 1 and Type 2 diabetes [4]. Conference Participation - Key executives from Genprex, including the President, CEO, and Chief Medical Officer, will be available for one-on-one meetings during the conference to discuss the company's gene therapies [2][3].